Ruibo Bio-B (06938) offered shares from December 31 to January 6 and was subscribed by Cornerstone Investment for approximately US$100 million

According to the Zhitong Finance App, Ruibo Biotech (06938) will raise shares from December 31, 2025 to January 6, 2026. The company plans to sell 27.4874 million H shares globally, of which Hong Kong sales account for 10%, international sales account for 90%, and overallotment rights of 15%. The sale price of each share is HK$57.97. H shares will be traded on the Stock Exchange at 9:00 a.m. on January 9, 2026 (Friday). H shares will be traded on the Stock Exchange using 200 H shares per lot.

We are a biopharmaceutical company engaged in research and development of small nucleic acid drugs, with a particular focus on siRNA therapy. We have RBD4059 (siRNA targeting FXI), a core product for treating thrombotic diseases. A total of seven self-developed drug assets are in clinical trials in the R&D pipeline, involving seven indications for cardiovascular, metabolic, kidney and liver diseases, four of which are in phase 2 clinical trials.

In addition to the core product RBD4059, we are also promoting other clinical-stage products, including RBD5044 and RBD1016. RBD5044 is the world's second clinically developed siRNA drug targeting APOC3 (a protein involved in lipid metabolism). RBD1016 aims to achieve functional healing of CHB through its effects on HBsAg, and is also a differentiated siRNA drug candidate for CHD. In addition to the clinical pipeline, we also have more than 20 pre-clinical projects, which we plan to advance to the clinical development stage.

We and the cornerstone investors Arc Avenue, Bright Stone, Huaxia Fund, Dacheng International and Dacheng Fund, Erik Selin Fastigheter AB, Himension Fund, IvyRock, Mingxin Growth Ventures, Springs Capital (Hong Kong), Taikang Life and Shibai Energy Trust, Natural Scuba and Huatai Capital Investment Limited (with respect to Huatai OTC swaps) entered into a Cornerstone Investment Agreement. Cornerstone investors have agreed to subscribe at the sale price or induce their designated entities to subscribe for the relevant number of shares that can be purchased for a total amount of about US$100 million, subject to certain conditions.

We believe that the Cornerstone Placement reflects the confidence of our Cornerstone investors in the Company and its business prospects, and that the Cornerstone Placement will help enhance the company's image. In addition to Erik Selin Fastigheter Aktiebolag (Erik Selin Fastigheter AB), the main shareholder of Ribocure AB, we met various cornerstone investors through an introduction from the overall coordinator of the global sale.

Based on the offering price of HK$57.97 per share and assuming that the right to adjust the sale volume and over-allotment rights are not exercised, it is estimated that we will receive approximately HK$1,474 billion in net proceeds from the global offering. Of this, about 37.4% will be used for R&D of the core product RBD4059; about 19.6% will be used for RBD5044 research and development; about 15.9% will be used for RBD1016 research and development; about 10.1% will fund the development of pipeline assets in the pre-clinical trial phase; about 8.9% will be allocated to advance the development of our pre-clinical assets and enhance our technology platform; about 8.1% will be used for working capital and other general corporate purposes.